Stockscreener 앱 받기
0.99
11.56%
0.1026
시간 외 거래:
1.03
0.04
+4.04%
전일 마감가:
$0.8874
열려 있는:
$0.896
하루 거래량:
2.80M
Relative Volume:
2.92
시가총액:
$40.47M
수익:
$5.12M
순이익/손실:
$-67.00M
주가수익비율:
-1.8746
EPS:
-0.5281
순현금흐름:
$-38.94M
1주 성능:
+14.68%
1개월 성능:
-36.94%
6개월 성능:
-88.71%
1년 성능:
-73.17%
1일 변동 폭
$0.85
$1.09
1주일 범위
$0.7919
$1.09
52주 변동 폭
$0.7043
$11.41
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
명칭
Verrica Pharmaceuticals Inc
전화
484-453-3300
주소
10 NORTH HIGH STREET, WEST CHESTER, PA
VRCA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| VRCA | 0.99 | 40.47M | 5.12M | -67.00M | -38.94M | -0.5281 |
| VRTX | 450.37 | 115.10B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.50 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.74 | 35.07B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.80 | 32.20B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.23 | 25.09B | 3.30B | -501.07M | 1.03B | 11.54 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2023-03-22 | 개시 | Jefferies | Buy |
| 2023-02-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 개시 | RBC Capital Mkts | Outperform |
| 2020-12-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-24 | 개시 | Northland Capital | Outperform |
| 2020-03-24 | 개시 | Needham | Buy |
| 2019-02-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica Prices of $42 Million Public Offering - citybiz
VRCAVerrica Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewswire
Verrica Pharmaceuticals Raises $42M Through Public Offering of Shares and Warrants | VRCA Stock News - StockTitan
Form 424B5 Verrica Pharmaceuticals - StreetInsider.com
Verrica Pharmaceuticals announces proposed public offering - MSN
Verrica Announces Proposed Public Offering - The Manila Times
Verrica Pharmaceuticals Announces Public Offering of Stock and Warrants with Jefferies | VRCA Stock News - StockTitan
Verrica Pharmaceuticals Reports Q3 2024 Financials and Restructuring Plans - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock - Investing.com
Verrica Pharmaceuticals' SWOT analysis: navigating challenges in dermatology stock By Investing.com - Investing.com UK
Q1 Earnings Forecast for VRCA Issued By HC Wainwright - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to “Neutral” at HC Wainwright - Defense World
Verrica downgraded to sector perform by RBC Capital - MSN
Verrica Pharmaceuticals’ (VRCA) Hold Rating Reaffirmed at Needham & Company LLC - Defense World
Biotech Alert: Searches spiking for these stocks today - TipRanks
Verrica Pharmaceuticals Announces Leadership Transition and Financial Results for Q3 2024 - Defense World
Verrica Pharmaceuticals (NASDAQ:VRCA) Cut to "Neutral" at HC Wainwright - MarketBeat
RBC Capital Downgrades Verrica Pharmaceuticals (VRCA) - MSN
Verrica Pharmaceuticals Reports Q3 2024 EPS of -$0.49 and Revenue of -$1.9 Million, Misses Estimates - GuruFocus.com
Verrica Pharmaceuticals stock hits 52-week low at $0.93 - Investing.com
U.S. Stock market: Bluejay Diagnostics (+105.33%), Zoomcar Holdings (+180.40%), and Verrica Pharmaceuticals(+39.10%) among the most volatile stocks during mid day trading - Business Upturn
Verrica Pharmaceuticals stock hits 52-week low at $0.93 By Investing.com - Investing.com South Africa
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Nasdaq Gains Over 100 Points; US Trade Deficit Widens In September - Benzinga
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Quarterly Earnings Results - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded to Sector Perform Rating by Royal Bank of Canada - MarketBeat
Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO - Marketscreener.com
Verrica Pharmaceuticals earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
Shares of Verrica Pharmaceuticals Tumble Following 3Q Results, Operational Changes - MarketWatch
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition - GlobeNewswire
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership - The Bakersfield Californian
Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring - TipRanks
Botanix Pharmaceuticals Poised for Market Impact with Sofdra Launch - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Short Interest Update - Defense World
Short Interest in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Expands By 24.8% - MarketBeat
Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewswire
Pharma Co. Verrica Faces Derivative Suit Over FDA Inspection - Law360
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) Given New $10.00 Price Target at TD Cowen - MarketBeat
Verrica shares price target cut by TD Cowen - Investing.com Canada
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc.VRCA - Business Wire
GLP-1 Receptor Agonist Market Set to Witness Significant Growth by 2024-2031:Verrica Pharmaceuticals, AbbVie - EIN News
Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... - Yahoo Finance
Verrica Pharmaceuticals reports board changes, non-compliance - Investing.com India
Verrica Pharmaceuticals reports board changes, non-compliance By Investing.com - Investing.com Australia
Recent Insider Activity Could Benefit Verrica Pharmaceuticals Inc (VRCA) - Knox Daily
Verrica Pharmaceuticals Strives for Nasdaq Compliance - TipRanks
Optinose Names Terry Kohler as CFO - MarketWatch
Optinose names Terry Kohler as new CFO By Investing.com - Investing.com UK
Verrica Pharmaceuticals Inc (VRCA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
3.55%
자본화:
|
볼륨(24시간):